logo-loader
Oncimmune

Oncimmune welcomes NHS review of cancer screenings

/**/ h1{margin-top:12.0pt;margin-right:0cm;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;font-size:16.0pt;font-family:"Arial","sans-serif";color:#2F5496;font-weight:normal;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: #0563C1 }visited{ color: #954F72 } .ac{size:595.05pt 840.85pt;margin:2.0cm 2.0cm 2.0cm 2.0cm;}div.ac{}p.ap{margin:0cm;margin-bottom:.0001pt;font-size:10.5pt;font-family:"Arial","sans-serif";font-weight: bold; text-align: center}span.an{font-size:11.0pt}p.aq{margin:0cm;margin-bottom:.0001pt;font-size:10.5pt;font-family:"Arial","sans-serif";font-weight: bold}p.a,li.a,div.a{margin:0cm;margin-bottom:.0001pt;font-size:10.5pt;font-family:"Arial","sans-serif";}p.ar{margin:0cm;margin-bottom:.0001pt;font-size:10.5pt;font-family:"Arial","sans-serif";text-align:justify}p.as{margin:0cm;margin-bottom:.0001pt;font-size:10.5pt;font-family:"Arial","sans-serif";font-weight: bold; text-align: justify}p.at{margin:0cm;margin-bottom:.0001pt;font-size:10.5pt;font-family:"Arial","sans-serif";font-div: italic; text-align: justify}p.au{margin:0cm;margin-bottom:.0001pt;font-size:10.5pt;font-family:"Arial","sans-serif";font-weight: bold; text-align: justify; vertical-align: baseline} span.av{color:#0563C1;text-decoration:underline;font-size:11.0pt}span.ag{font-size: 11.0pt}p.ae{ font-weight: bold; margin: 0cm; margin-bottom: .0001pt; text-align: justify}span.af{font-size:11.0pt;font-family:"Arial","sans-serif"}span.ad{font-size:11.0pt;color:windowtext} /**/
RNS Number : 1382Q
Oncimmune Holdings PLC
16 October 2019
 

Oncimmune Holdings plc

("Oncimmune", the "Company" or the "Group")

 

 

NHS review of national cancer screening programmes in England welcomed by Oncimmune

 

 

16 October, 2019 - Oncimmune Holdings plc (AIM:ONC.L), the leading global immunodiagnostics group, welcomes today's publication of the Independent Review of Adult Screening Programmes in England, which makes recommendations on overhauling national cancer screening programmes to aid earlier diagnosis and treatment. 

 

Oncimmune's EarlyCDT Lung test, which uses a simple blood sample, can detect lung cancer on average four years or more before standard clinical diagnosis.

 

Over 12,000 people in Scotland at high risk of developing lung cancer were tested with EarlyCDT Lung in the recently announced Early detection of Cancer of the Lung Scotland (ECLS) trial. The study showed that more people were diagnosed at an early stage of the disease in the two years after taking the test than those in the control arm who received standard clinical care. The findings were presented last month at the World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer and have now been submitted for publication in a leading medical journal.

 

Oncimmune is also working to make EarlyCDT Lung available to help diagnose lung cancer earlier in a range of other countries including the United States, Spain, Russia and China. 

 

Oncimmune's patented technology harnesses the power of the immune system to detect evidence of the body's natural response to cancer. Tests to diagnose other forms of cancer, including, ovarian, breast and prostate using a simple blood test are in development.

 

A link to the Report of The Independent Review of Adult Screening Programmes in England can be found at https://www.england.nhs.uk/wp-content/uploads/2019/02/report-of-the-independent-review-of-adult-screening-programme-in-england.pdf

 

 

Dr Adam Hill, Chief Executive Officer of Oncimmune, commented:

 

"The Independent Review makes sensible, practical recommendations towards making early cancer diagnosis more accessible to all. Early diagnosis is critical to improving cancer survival. Our test for lung cancer is easy to perform, quick to analyse and available right now. It has the potential to save lives as part of a targeted screening program as well as significantly reducing costs for the NHS.  We look forward to continuing to work with screening experts throughout the UK to roll EarlyCDT Lung out more widely."

 

For further information:

 

Oncimmune Holdings plc

Dr Adam Hill, Chief Executive Officer

Magda Bartoszewicz, Head of Marketing

[email protected]

+44 115 823 1869

Cléa Rosenfeld, Head of Investor Relations

[email protected] 

 

Media enquiries:

FTI Consulting

Brett Pollard, Andrew Ward

[email protected] 

+44 (0)20 3727 1000

 

About Oncimmune

 

Beating cancer, one test at a time

 

The battle against cancer hinges on early detection and then the delivery of effective treatment. Oncimmune is working to revolutionise both the detection of cancer and its treatment by harnessing the sophisticated disease detecting capabilities of the immune system to find cancer in its early stages. Our range of diagnostic tests assist clinicians to identify the presence of cancer four years or more before standard clinical diagnosis, whilst our technology platform and sample biobanks are helping healthcare companies to develop new cancer treatments.

 

Oncimmune was founded in 2002 and launched its platform technology in 2009, followed by its first commercial tests, EarlyCDT Lung and EarlyCDT Liver. To date, over 155,000 tests have been performed for patients worldwide. EarlyCDT Lung was also used in what is believed to be the largest randomised controlled study for the early detection of lung cancer using biomarkers, the successful National Health Service (NHS) ECLS study of 12,209 high-risk smokers in Scotland which demonstrated EarlyCDT Lung reduced the incidence of patients with late-stage lung cancer or unclassified presentation at diagnosis, compared to standard clinical practice.

 

Oncimmune, headquartered at its laboratory facility in Nottingham, UK, has a discovery research centre in Dortmund, Germany and a CLIA lab in Kansas, US as well as an office in London, UK and a partner representative office in Shanghai, China. Oncimmune joined the Alternative Investment Market (AIM) of the London Stock Exchange in May 2016 under the ticker ONC.L.

 

What is EarlyCDT Lung?

 

A blood test using a panel of seven immunogenic proteins for the testing of tumour-related antibodies specific to lung cancer.

 

For more information, visit www.oncimmune.com


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
NRAMFBATMBABBFL

Quick facts: Oncimmune

Price: 51

Market: AIM
Market Cap: £32.26 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

New US deal for Oncimmune on the back of mixed results

Oncimmune Holdings PLC (LON:ONC) has inked a new deal with US diagnostics firm Biodesix for its EarlyCDT lung cancer test. CEO Adam Hill tells Proactive London how significant the deal is and lays out his new three year strategic vision for the company, underlining a newly-implemented and...

1 week, 5 days ago